Roivant Sciences' stock posted a strong intraday advance, rising nearly 14.0% after the company released fiscal fourth-quarter 2026 results before markets opened. The quarter produced a surprise on the bottom line: diluted earnings per share of $0.28 versus the analyst consensus that had pointed to a loss of $0.29 - a positive surprise of nearly 197% relative to expectations.
The company attributed much of the swing in earnings to a $770.2 million gain linked to a litigation settlement with Moderna, which helped lift net income to $302.99 million compared with a net loss of $206.48 million in the same quarter a year earlier. Reported revenue totaled $2.52 million, below the $3.76 million consensus. Market participants largely discounted the top-line shortfall given the scale of the earnings beat and the non-recurring nature of the settlement gain.
Balance sheet strength was another explicit factor cited by investors. Roivant entered the report with $4.3 billion in cash and no debt on the balance sheet, while continuing to execute share repurchase programs. Management also emphasized a $2.25 billion total settlement with Moderna, structured to include a $950 million upfront payment expected in July 2026. That payment and the broader settlement framework were clearly material contributors to the quarter's reported results.
Beyond the settlement, the company outlined multiple near-term clinical milestones that supported the market's positive reaction. Priovant is positioned to seek a commercial launch of brepocitinib for dermatomyositis by the end of September 2026, following FDA acceptance of the drug's New Drug Application with Priority Review. Pulmovant plans to report topline Phase 2 data for mosliciguat in pulmonary hypertension-associated interstitial lung disease in late 2026. The company reiterated a strategic focus on mosliciguat and highlighted expectations for Phase 2 data in the second half of 2026.
Investor appetite for Roivant's broader portfolio appeared to spill over to affiliated assets, with Immunovant shares moving sharply higher in sympathy. Technical and market context also supported the stock move. The S&P 500 rose 0.9% on the session, the Dow Jones Industrial Average climbed 0.9%, and the NASDAQ gained 1.3%, providing a constructive tape that amplified company-specific catalysts. Traders noted that ROIV had outperformed roughly 95% of stocks over the prior year and had been trading in a tight consolidation near multi-year highs prior to the earnings release - the report acted as a breakout trigger for those watching the chart patterns.
Taken together, the quarter's results combined a historic EPS beat, a substantial litigation settlement windfall, a strong liquidity position and multiple upcoming clinical milestones to form a layered rationale for the rally. While the settlement gain was clearly a one-time benefit to earnings in the quarter, management emphasized continued operational progress across therapeutic programs and the expectation of meaningful upcoming data readouts across several subsidiaries.
What this means for markets
- Biopharmaceutical and specialty biotech shares responded positively, driven by the magnitude of the one-time settlement and clear near-term development catalysts.
- Investors appear willing to look beyond the revenue miss given the settlement's impact on reported earnings and the company's cash-rich, debt-free position.
- Broader market strength on the day provided a favorable backdrop that helped accentuate the stock-specific move.
Limitations in the company discussion remain clear: the substantial earnings beat was materially affected by a litigation settlement, and reported revenue declined versus consensus. Market participants will likely continue to parse upcoming clinical milestones and the timing of settlement proceeds to assess how much of the recent price move reflects durable progress versus a short-term reaction to a large one-off item.